ClinConnect ClinConnect Logo
Search / Trial NCT05897320

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Launched by H. LUNDBECK A/S · May 31, 2023

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called eptinezumab to see if it can help reduce the number of days children and teenagers experience episodic migraines, which are headaches that come and go rather than being constant. The trial is currently looking for participants aged 2 to 17 who have been diagnosed with migraines for at least six months. To be eligible, participants must have had fewer than 14 headache days in the past month, and at least 4 of those must have been migraine days as tracked in a headache diary.

If your child participates, they will be asked to complete a headache diary for 28 days to record their headache days. This helps the researchers understand how well eptinezumab works. Participants will also receive regular check-ins with healthcare providers throughout the study. It's important to note that children with certain other types of headaches, neurological disorders, or untreated psychiatric conditions may not be eligible for this trial. Overall, this study aims to find effective ways to help young people manage their migraines better.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders, 3rd edition (ICHD-3; in the opinion of the investigator) with history of migraine headaches of at least 6 months prior to the Screening Visit.
  • During the 28-day screening period, the participant (and their parent/caregiver, when applicable) must adequately complete the headache eDiary (≥23 of the 28 days) following the day of the Screening Visit.
  • During the 28-day screening period, the participant must have ≤14 headache days, of which at least 4 are migraine days as documented in the eDiary.
  • Exclusion Criteria:
  • History or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes (previously referred to as complicated migraine), such as hemiplegic migraine (sporadic and familial), migraine with brainstem aura, recurrent painful ophthalmic neuropathy, or migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration, e.g., \>60 min).
  • History of moderate or severe head trauma or other neurological disorder or systemic medical disease that is, in the investigator's opinion, likely to affect the functions of the central nervous system.
  • Current psychiatric condition that is uncontrolled and/or untreated for a minimum of 6 months prior to the Screening Visit. Participants with a lifetime history of psychosis and/or mania are excluded.
  • Any other disorder for which the treatment takes priority over treatment of migraine or is likely to interfere with study treatment or impair treatment compliance.
  • Other inclusion and exclusion criteria may apply.

About H. Lundbeck A/S

H. Lundbeck A/S is a global pharmaceutical company dedicated to improving the quality of life for patients with brain disorders. Founded in 1915 and headquartered in Denmark, Lundbeck specializes in research, development, manufacturing, and marketing of innovative treatments for conditions such as depression, schizophrenia, and Alzheimer's disease. With a strong commitment to neuroscience, Lundbeck invests significantly in clinical trials to advance the understanding and treatment of psychiatric and neurological disorders, aiming to deliver effective solutions that address unmet medical needs worldwide.

Locations

Tampa, Florida, United States

Madrid, , Spain

Valencia, , Spain

Novi Sad, , Serbia

Great Yarmouth, Norfolk, United Kingdom

Victoria, British Columbia, Canada

Cordoba, , Argentina

Braga, , Portugal

Belgrade, , Serbia

Lisboa, , Portugal

Kragujevac, , Serbia

Coimbra, , Portugal

Genova, Liguria, Italy

Milano, Lombardia, Italy

Vigo, Pontevedra, Spain

Milano, Lombardia, Italy

Stamford, Connecticut, United States

Oswiecim, , Poland

Ajax, Ontario, Canada

Cincinnati, Ohio, United States

Río Cuarto, Córdoba, Argentina

Firenze, Toscana, Italy

Nis, , Serbia

Novi Sad, , Serbia

Hialeah, Florida, United States

Lexington, Kentucky, United States

Ann Arbor, Michigan, United States

Norfolk, Virginia, United States

Ciudad Autonoma De Buenos Aires, Ciudad Autonoma De Buenosaires, Argentina

Pavia, Lombardia, Italy

Barcelona, , Spain

Río Cuarto, Cordoba, Argentina

Charlotte, North Carolina, United States

Gulf Breeze, Florida, United States

Commack, New York, United States

San Antonio, Texas, United States

Rosario, Santa Fe, Argentina

Penticton, British Columbia, Canada

Milano, Lombardia, Italy

Baltimore, Maryland, United States

Charlotte, North Carolina, United States

Glasgow, Glasgow City, United Kingdom

Porto Covo, Setúbal, Portugal

Pisa, Toscana, Italy

Munro, Buenos Aires, Argentina

San Miguel De Tucuman, Tucuman, Argentina

Roma, Lazio, Italy

Pavia, Lombardia, Italy

Tepetlacalco, , Mexico

Coimbra, , Portugal

Eskisehir, , Turkey

Warszawa, Mazowieckie, Poland

Akron, Ohio, United States

Norfolk, Virginia, United States

Barracas, Ciudad Autonoma De Buenosaires, Argentina

Pisa, Toscana, Italy

Porto Covo, Setúbal, Portugal

Braga, , Portugal

San Miguel De Tucuman, Tucumán, Argentina

Ciudad Autonoma De Buenos Aires, Ciudad Autonoma De Buenosaires, Argentina

Rosario, Santa Fe, Argentina

Fatih/Istanbul, , Turkey

New Berlin, Wisconsin, United States

Eskisehir, , Turkey

Mersin, , Turkey

Ciudad Autónoma De Buenos Aires, Ciudad Autónoma De Buenosaires, Argentina

Porto Covo, , Portugal

Porto Covo, Setúbal, Portugal

Coimbra, , Portugal

Barracas, Ciudad Autónoma De Buenosaires, Argentina

Roma, Lazio, Italy

Bayraklı, Izmir, Turkey

London, Ontario, Canada

Edinburgh, Midlothian, United Kingdom

Río Cuarto, , Argentina

Ciudad Autónoma De Buenos Aires, , Argentina

San Miguel De Tucuman, , Argentina

Edinburgh, Midlothian, United Kingdom

Porto Covo, , Portugal

Barracas, , Argentina

Lublin, , Poland

Warszawa, , Poland

Patients applied

0 patients applied

Trial Officials

Email contact via H. Lundbeck A/S

Study Director

LundbeckClinicalTrials@Lundbeck.com

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported